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Hypothesis

Research Background

Diffuse Intrinsic Pontine Glioma (DIPG) is a glial tumor occurring
primarily in children with extremely poor prognosis. Occurring
outside of the pons, surgery following diagnosis is not viable for
DIPG patients as the location of the tumor is vital for motor
functions. There has yet to be a significant improvement in the
survival median rate upon diagnosis outside of the effects of radiation
therapy. Though radiation therapy has proven to improve neurological
symptoms of DIPG patients, the results of this treatment have proven
to be transitory at best. Currently, there is an interest in looking at
specific oncogenic targets to find the most efficacious biological
agent(s) to decrease tumor cell growth.
Mithramycin is a relatively new anticancer drug reported to be
effective against variety of cancers. It blocks Specificity protein-1
(Sp1) from binding to DNA through its guanine-cytosine
(G-C)-specific DNA-binding ability and selectively downregulates
an X-linked inhibitor of apoptosis protein (XIAP) levels, therefore
increasing levels of apoptosis in cancer cells. SET Domain Bifurcated
Histone Lysine Methyltransferase 1 (coded by SETDB1 gene) is an
enzyme that reversibly catalyzes methylation in Histone 3 K9
(H3K9). SETDB1 is heavily involved in the downregulation of vital
tumor-suppressive genes, adding to its pro-oncogenic nature and is
recently found to be overexpressed in DIPGs by our lab. Mithramycin
was reported to be a SETDB1 inhibitor by blocking the interaction
between SP-1 and SETDB1 regulatory sites.

Since oncogenic proteins REST and SET DB1 interacts with each other and are overexpressed in DIPGs, targeting their
expression/blocking interaction may prove a novel therapeutic approach. Using mithramycin may result in interfering with SET
DB1 and REST oncogenic interaction and inhibit DIPG proliferation.

Methods

Cell Culture
TSM base media was prepared by mixing equal volumes of Neurobasal-A and DMEM/F12 mix along with growth factors. Fresh
culture media was prepared by adding EGF, FGC, PDGF, Heparin and other growth factors in TSM base medium and used to
culture all three cell lines.
Treatments
Mithramycin was dissolved in DMSO at 10mM concentration followed by serial dilutions in complete media. 10 & 100uM
Stocks were used to administer treatments in 96 well plates for 120 hours.
MTT Assay
Cells were plated in 96-well plates for an incubation period of 120 hours. For adherent cells, media is suctioned from the plate.
For suspension cells, cells are centrifuged at 4 degrees Celsius for 5 minutes before media is sanctioned. 50uL of media per
well followed by 50uL of MTT solution per well is added to 96-well plates. Cells are incubated at 37 degrees Celsius for 4
hours. Following incubation, 150 uL of MTT solvent is added to each well. Absorbance is read at OD=590nm within 1 hour.
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Fiigure 2. (A) REST and SET DB1 interaction shown via IP (B) SET DB1 expression is also elevated in DIPG and (C) SET DB1 knockout decreases DIPG
proliferation. ChIP experiment showing REST (D), SET DB1 (E) and H3K9me3 (F) on caveolin-1 promoter.
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Figure 3: Cell cycle analysis of DIPG 7 and DIPG 7REST cells upon 72 hours treatment
With Mithramycin.

Summary of Results
REST and SET DB1 are overexpressed in DIPG
tumors and contribute to proliferative potential.
Interaction of REST and SET DB1 indicates
towards cooperative oncogenic behavior in
DIPGs.
REST and SET DB 1 occupies Caveolin -1
promoter and induce trimethylation of H3K9.
Targeting SET DB1 expression using
Mithramycin results in significant decrease in
cell proliferation in all DIPG cell lines.
Slightly lower toxicity in REST high cell lines
indicate REST might be rescuing against loss of
SET DB1 expression.
Cell Cycle analysis showed decreased population
in G2/M phase for DIPG7 cells while in DIPG
7REST, there is significant decrease in cell
populations in S and G2/M phase.

Conclusions

Figure 1: (A) REST complex & its binding to RE1 sites. (B) REST expression
in DIPGs. (C) ChIPseq shows decreased expression of genes where
promoters are bound by REST in DIPGs. (D) ATACseq and RNAseq
combined analysis revealed REST and SETDB1 are hyperactive TFs in
DIPGs. (E) REST knockdown block DIPG tumors and increase survival in
mice models.
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Mithramycin is able to induce cell death in
DIPG cell lines.
REST-SET DB1 interaction axis is need to be
evaluated for its potential impact on DIPG
tumor survival.
Detailed mechanism of Mithramycin action is
needed to be elucidated.
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